Abstract

Lipid abnormalities are among the key risk factors for cardiovascular disease. Indeed, lipid-modifying drugs — in particular, the statins, which primarily lower plasma levels of low-density lipoprotein (LDL) cholesterol — considerably reduce the risk of cardiovascular events, leading to their widespread use. Nevertheless, it seems that there might be limits to the degree of benefit that can be achieved by lowering LDL-cholesterol levels alone, which has led to increased interest in targeting other lipid-related risk factors for cardiovascular disease, such as low levels of high-density lipoprotein (HDL) cholesterol. In this article, we first consider the mechanisms that underlie the protective effect of HDL cholesterol, and then discuss several strategies that have recently emerged to increase levels of HDL cholesterol to treat cardiovascular disease, including nuclear receptor modulation, inhibition of cholesteryl ester transfer protein and infusion of apolipoprotein/phospholipid complexes.

Author affiliations

1. Division of Molecular Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10027, USA.

Correspondence to: Patrick Linsel-Nitschke¹ Email: pl2031@columbia.edu

Correspondence to: Alan R. Tall¹ Email: art1@columbia.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.